keyword
MENU ▼
Read by QxMD icon Read
search

Generic drug pricing

keyword
https://www.readbyqxmd.com/read/28224469/the-medicaid-rebate-changes-in-oncology-drug-prices-after-the-affordable-care-act
#1
Ali Bonakdar Tehrani, Norman V Carroll
BACKGROUND: Prescription drug spending is a significant component of Medicaid total expenditures. The Affordable Care Act (ACA) includes a provision that increases the Medicaid rebate for both brand-name and generic drugs. This study examines the extent to which oncology drug prices changed after the increase in the Medicaid rebate in 2010. METHODS: A pre-post study design was used to evaluate the correlation between the Medicaid rebate increase and oncology drug prices after 2010 using 2006-2013 State Drug Utilization Data...
February 21, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28212657/pharmacists-views-and-reported-practices-in-relation-to-a-new-generic-drug-substitution-policy-in-lebanon-a-mixed-methods-study
#2
Fadi El-Jardali, Racha Fadlallah, Rami Z Morsi, Nour Hemadi, Mounir Al-Gibbawi, Magda Haj, Suzan Khalil, Youssef Saklawi, Diana Jamal, Elie A Akl
BACKGROUND: Governments in both developed and developing countries have adopted generic drug substitution policies to decrease pharmaceutical expenditures and improve access to medicine. In August 2015, the Ministry of Public Health (MOPH) in Lebanon introduced generic drug substitution and a unified medical prescription form as policy instruments to promote generic drug use. The objective of this exploratory study was to examine the attitudes of community pharmacists and the reported practices in relation to the implementation of the new generic drug substitution policy...
February 17, 2017: Implementation Science: IS
https://www.readbyqxmd.com/read/28138932/drug-pricing-in-south-korea
#3
Hye-Young Kwon, Brian Godman
Between 2000 and 2013, spending on medicines in Korea increased by 275.3%. In order to curb this trend, several pricing policies and measures were introduced. This study reviews these policies and their implications based on pricing regulations as well as a literature review. New medicines now undergo both a reimbursement assessment and price negotiations. The reimbursement of new medicines is based on their cost effectiveness. The prices of new medicines are subsequently fixed through negotiations between the payer, the National Health Insurance Service, and the relevant manufacturer...
January 30, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28120334/price-variation-in-the-most-commonly-prescribed-ear-drops-in-southern-california
#4
Omid Moshtaghi, Yarah M Haidar, Yaser Ghavami, Jeff Gu, Afsheen Moshtaghi, Ronald Sahyouni, Melissa Huang, Harrison W Lin, Hamid R Djalilian
OBJECTIVES/HYPOTHESIS: To evaluate the variability and discrepancies among the most commonly prescribed ear drops sold at pharmacies in southern California. STUDY DESIGN: Prospective study evaluating 11 commonly used ear drops to treat otologic disorders. METHODS: Randomly selected drug stores in three major counties in Southern California (Los Angeles, Orange, and San Diego) were included. Mean, range, minimum, and maximum prices for each drug were calculated and analyzed...
January 24, 2017: Laryngoscope
https://www.readbyqxmd.com/read/28114637/high-prices-for-drugs-with-generic-alternatives-the-curious-case-of-duexis
#5
Aaron Hakim, Joseph S Ross
No abstract text is available yet for this article.
January 23, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28110283/estimated-generic-prices-of-cancer-medicines-deemed-cost-ineffective-in-england-a-cost-estimation-analysis
#6
Andrew Hill, Christopher Redd, Dzintars Gotham, Isabelle Erbacher, Jonathan Meldrum, Ryo Harada
OBJECTIVES: The aim of this study was to estimate lowest possible treatment costs for four novel cancer drugs, hypothesising that generic manufacturing could significantly reduce treatment costs. SETTING: This research was carried out in a non-clinical research setting using secondary data. PARTICIPANTS: There were no human participants in the study. Four drugs were selected for the study: bortezomib, dasatinib, everolimus and gefitinib. These medications were selected according to their clinical importance, novel pharmaceutical actions and the availability of generic price data...
January 20, 2017: BMJ Open
https://www.readbyqxmd.com/read/28073970/estimated-generic-prices-for-novel-treatments-for-drug-resistant-tuberculosis
#7
Dzintars Gotham, Joseph Fortunak, Anton Pozniak, Saye Khoo, Graham Cooke, Frederick E Nytko, Andrew Hill
BACKGROUND: The estimated worldwide annual incidence of MDR-TB is 480 000, representing 5% of TB incidence, but 20% of mortality. Multiple drugs have recently been developed or repurposed for the treatment of MDR-TB. Currently, treatment for MDR-TB costs thousands of dollars per course. OBJECTIVES: To estimate generic prices for novel TB drugs that would be achievable given large-scale competitive manufacture. METHODS: Prices for linezolid, moxifloxacin and clofazimine were estimated based on per-kilogram prices of the active pharmaceutical ingredient (API)...
January 10, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28065194/osteoporosis-drugs-marketed-in-the-united-states-generic-competition-pricing-structure-and-dispersion-among-payers
#8
Bander Balkhi, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio
BACKGROUND: Despite the cost of pharmaceuticals, studies assessing prices of osteoporosis drugs are lacking. This study examined trends in prices of osteoporosis drugs in the United States in the period 1988-2014, assessed pricing structure of osteoporosis drugs, and evaluated price trends before and after generic drugs market entry. METHODS: Data were derived from the U.S. Food and Drug Administration, the RedBook, the Centers for Medicare & Medicaid Services, and the Federal Supply Schedule (FSS)...
January 9, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28052986/can-voluntary-pooled-procurement-reduce-the-price-of-antiretroviral-drugs-a-case-study-of-efavirenz
#9
Sung Wook Kim, Jolene Skordis-Worrall
PURPOSE: A number of strategies have aimed to assist countries in procuring antiretroviral therapy (ARV) at lower prices. In 2009, as the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) commenced a voluntary pooled procurement scheme, however, the impact of the scheme on ARV prices remains uncertain. This study aims to estimate the effect of VPP on drug prices using Efavirenz as a case study. METHODS: This analysis uses WHO Global price report mechanism (GPRM) data from 2004 to 2013...
January 4, 2017: Health Policy and Planning
https://www.readbyqxmd.com/read/27995636/managing-the-rising-costs-and-high-drug-expenditures-in-critical-care-pharmacy-practice
#10
Alexander H Flannery, Komal Pandya, Melanie E Laine, Philip J Almeter, Jeremy D Flynn
Pharmaceutical costs for patients in the intensive care unit (ICU) constitute a large portion of hospital drug budgets. Unfortunately, prices for medications commonly used in the ICU are on the rise for a variety of reasons. In particular, the U.S. Food and Drug Administration's Unapproved Drugs Initiative, generic manufacturers cornering the marketplace, drug shortages, and regulatory device changes are major drivers of pharmaceutical price escalation affecting costs in the ICU. Furthermore, traditional high acquisition cost items still pose challenges to controlling costs...
January 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/27993771/states-sue-generic-drug-makers-for-alleged-price-fixing
#11
Michael McCarthy
No abstract text is available yet for this article.
December 19, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27987628/arbitration-board-setting-reimbursement-amounts-for-pharmaceutical-innovations-in-germany-when-price-negations-between-payers-and-manufacturers-fail-an-empirical-analysis-of-5-years-experience
#12
Saskia Ludwig, Charalabos-Markos Dintsios
BACKGROUND: In Germany, an arbitration board is setting reimbursement amounts for drug innovations when price negations between payers and manufacturers fail. OBJECTIVE: To empirically analyze all arbitrations since the reform of Germany's Act to Reorganize the Pharmaceuticals' Market in the Statutory Health Insurance System came into effect. METHODS: All available relevant documents up to January 2016 were screened and the identified contentious issues between the negotiation parties extracted...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27936981/the-impact-of-price-cap-regulations-on-market-entry-by-generic-pharmaceutical-firms
#13
Wei Zhang, Huiying Sun, Daphne Guh, Aslam H Anis
BACKGROUND: In 1998, the province of Ontario, Canada implemented price-cap '70/90' regulations: the first generic must be priced at ≤70% of the associated brand-name price and subsequent generics must be priced at ≤90% of the first generics' price. The price-cap was further lowered to 50% in 2006 and 25% in 2010 for all generic drugs regardless of the first or subsequent generic entrants. This study assessed the impact of such price-cap regulations on market entry by generic firms using the formulary database from 9 provinces (January 2004-March 2013)...
December 27, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27931985/impact-of-regulatory-measures-on-antipsychotics-drug-consumption-in-castilla-y-le%C3%A3-n-spain
#14
L H Martín Arias, C Treceño Lobato, S Pérez García, P García Ortega, M Sáinz Gil, R Sanz Fadrique, A Carvajal García-Pando
OBJECTIVES: Antipsychotics are currently used to treat different diseases; even some off-labelled conditions are treated with this medication. Consumption and cost of antipsychotic drugs sharply increased in Spain after second-generation drugs were marketed; several regulatory measures were adopted to curb this trend. The aim of this study was to examine the impact of these measures upon the use and cost of antipsychotics. STUDY DESIGN: Study of drug use (SDU) from 1995 to 2012...
December 2016: Public Health
https://www.readbyqxmd.com/read/27881273/the-effects-of-the-new-methodology-application-on-the-method-of-pricing-of-drugs-the-case-of-the-republic-of-macedonia
#15
Rubin Zareski, A Kapedanovska Nestorovska, A Grozdanova, B Dimitrova, L J Suturkova, Z Sterjev
BACKGROUND: The introduction of a new methodology for the pricing of drugs by the Agency of Medicines of the Republic of Macedonia for the period 2012 to 2015 resulted in a price reduction of 1386 drugs. OBJECTIVE: This pioneer study evaluated the effects of the price changes during this period of 4 years and the consequent effects on the sale quantities for the segmented Anatomical Therapeutic Chemical groups. METHODS: The drugs were grouped by the size of the reductions, by segmenting the drugs by generic names, and by the Anatomical Therapeutic Chemical classification, in which the quantities are grouped by generic names and the prices are calculated by average values for a period of 1 year...
September 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27881258/cost-effectiveness-analysis-of-tocilizumab-in-comparison-with-infliximab-in-iranian-rheumatoid-arthritis-patients-with-inadequate-response-to-tdmards-a-multistage-markov-model
#16
Amir Hashemi-Meshkini, Shekoufeh Nikfar, Elizabeth Glaser, Ahmadreza Jamshidi, Seyed Alireza Hosseini
OBJECTIVES: To analyze the cost-effectiveness of two common treatment strategies in Iran, comparing infliximab plus methotrexate with tocilizumab plus methotrexate in patients with rheumatoid arthritis with inadequate response to traditional disease-modifying antirheumatic drugs. METHODS: A multistage Markov decision model was applied to assess the incremental cost-effectiveness ratio (ICER) of a tocilizumab-containing regimen versus an infliximab-containing regimen over a 5-year time period...
May 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27862588/comparative-analysis-of-the-cost-and-effectiveness-of-generic-and-brand-name-antibiotics-the-case-of-uncomplicated-urinary-tract-infection
#17
Yu-Shiuan Lin, I-Shiow Jan, Shou-Hsia Cheng
PURPOSE: Generic medications used for chronic diseases are beneficial in containing healthcare costs and improving drug accessibility. However, the effects of generic drugs in acute and severe illness remain controversial. This study aims to investigate treatment costs and outcomes of generic antibiotics prescribed for adults with a urinary tract infection in outpatient settings. METHODS: The data source was the Longitudinal Health Insurance Database of Taiwan. We included outpatients aged 20 years and above with a urinary tract infection who required one oral antibiotic for which brand-name and generic products were simultaneously available...
November 8, 2016: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/27846638/variability-in-retail-pricing-of-generic-drugs-for-heart-failure
#18
Paul J Hauptman, Zackary D Goff, Andrija Vidic, John T Chibnall, Barry E Bleske
No abstract text is available yet for this article.
January 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/27802935/competition-authority-will-investigate-price-hikes-of-generic-drugs
#19
Nigel Hawkes
No abstract text is available yet for this article.
November 1, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27781100/how-can-we-achieve-universal-access-to-low-cost-treatment-for-hiv
#20
EDITORIAL
Andrew M Hill, Anton L Pozniak
Mass production of low-cost antiretrovirals (ARVs) has already allowed over 17 million individuals to access treatment for HIV infection, mainly in low-income countries. It is possible to manufacture combination ARVs for $110 per person-year, using tenofovir (TDF), lamivudine (3TC) and efavirenz (EFV). New combinations of ARVs costing as little as $60 per person-year will be available in the near future. Pre-exposure prophylaxis using TDF in combination with either 3TC or emtricitabine (FTC) could also be provided for less than $90 per person-year...
October 5, 2016: Journal of Virus Eradication
keyword
keyword
67607
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"